Guggenheim Capital LLC grew its holdings in Baxter International Inc (NYSE:BAX) by 3.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 781,380 shares of the medical instruments supplier’s stock after purchasing an additional 29,668 shares during the period. Guggenheim Capital LLC owned about 0.14% of Baxter International worth $50,509,000 as of its most recent SEC filing.
Several other institutional investors have also bought and sold shares of BAX. Family Capital Trust Co bought a new stake in shares of Baxter International in the fourth quarter worth $103,000. Community Bank N.A. grew its holdings in shares of Baxter International by 152.7% in the fourth quarter. Community Bank N.A. now owns 1,655 shares of the medical instruments supplier’s stock worth $107,000 after acquiring an additional 1,000 shares during the period. Trustcore Financial Services LLC bought a new stake in shares of Baxter International in the fourth quarter worth $131,000. Grove Bank & Trust grew its holdings in shares of Baxter International by 526.0% in the third quarter. Grove Bank & Trust now owns 2,285 shares of the medical instruments supplier’s stock worth $143,000 after acquiring an additional 1,920 shares during the period. Finally, Truewealth LLC bought a new stake in shares of Baxter International in the fourth quarter worth $159,000. 85.56% of the stock is owned by institutional investors and hedge funds.
In other news, Director Carole J. Shapazian sold 4,990 shares of the business’s stock in a transaction dated Friday, March 2nd. The stock was sold at an average price of $66.05, for a total value of $329,589.50. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Giuseppe Accogli sold 28,641 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $67.00, for a total value of $1,918,947.00. The disclosure for this sale can be found here. 0.05% of the stock is owned by insiders.
Shares of Baxter International Inc (BAX) opened at $67.89 on Friday. Baxter International Inc has a fifty-two week low of $51.03 and a fifty-two week high of $72.58. The stock has a market capitalization of $36,507.98, a PE ratio of 52.63, a price-to-earnings-growth ratio of 1.95 and a beta of 0.82. The company has a current ratio of 2.57, a quick ratio of 2.05 and a debt-to-equity ratio of 0.38.
Baxter International (NYSE:BAX) last announced its quarterly earnings data on Thursday, February 1st. The medical instruments supplier reported $0.64 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.59 by $0.05. Baxter International had a return on equity of 15.11% and a net margin of 6.79%. The business had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.77 billion. During the same period in the previous year, the business earned $0.57 earnings per share. The business’s revenue was up 4.9% on a year-over-year basis. equities research analysts expect that Baxter International Inc will post 2.78 EPS for the current fiscal year.
Baxter International declared that its Board of Directors has approved a stock buyback plan on Tuesday, February 20th that allows the company to repurchase $1.50 billion in outstanding shares. This repurchase authorization allows the medical instruments supplier to purchase shares of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its shares are undervalued.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, April 2nd. Stockholders of record on Friday, March 2nd will be given a $0.16 dividend. The ex-dividend date is Thursday, March 1st. This represents a $0.64 annualized dividend and a dividend yield of 0.94%. Baxter International’s payout ratio is 49.61%.
Baxter International Profile
Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.
Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.